About this trial
Screening for risk factors related to lung function impairment in patients who have recovered from AIDS with severe pneumonia, to provide clinical evidence for early identification and intervention of lung function damage in this population.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Confirmed HIV infection;
Progression to the AIDS stage: CD4+ count <200 cells/µL and/or occurrence of opportunistic infections associated with AIDS;
Age between 18 to 65 years;
Meet the diagnostic criteria for severe pneumonia, with reference to the 2021 treatment guidelines for community-acquired pneumonia developed by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA).
Disqualifiers
Concurrent central nervous system lesions, severe liver disease, or cirrhosis;
Concurrent AIDS-related or non-related tumors;
Women who are pregnant or breastfeeding;
Presence of serious underlying diseases such as heart, lung, liver, kidney, etc.;
Trial population
All study participants come from the HIV/HBV co-infection cohort at the Guangzhou Eighth People's Hospital.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Obstructive Ventilatory Dysfunction
FEV1(Forced Expiratory Volume in One Second )to FVC (Forced Vital Capacity ) Ratio
Secondary outcomes
FEV1
FEV1 decrease of ≥100 mL
Sponsors and contacts
Click on the lead sponsor to view all of their trials.